Befrena Injection
Befrena Injection (tirnovetmab) is a long-lasting injectable anti-IL-31 monoclonal antibody for dogs that controls allergic dermatitis and canine atopic dermatitis itch within 24 hours and provides 6–8 weeks of relief.
Description
Befrena Injection
Long-lasting injectable anti-itch therapy providing 6–8 weeks of relief from allergic and atopic dermatitis in dogs.
Manufactured/Marketed by: Elanco Animal Health
Country of Origin: USA
Dosage form: Injectable Solution
Presentation:
Single-use vials:
0.5 mL vial
1.0 mL vial
1.5 mL vial
2.0 mL vial
(Combination of vials selected according to dog body weight requirement)
Ingredients & Composition:
Tirnovetmab – Anti-Interleukin-31 (IL-31) monoclonal antibody
Injectable formulation q.s.
Description / Action:
Befrena contains tirnovetmab, an injectable monoclonal antibody designed specifically to control canine allergic itch.
IL-31 is a key cytokine responsible for transmitting itch signals in allergic and atopic dermatitis.
Tirnovetmab binds selectively to a unique sequence on IL-31 cytokine.
Prevents IL-31 from binding with peripheral nerve receptors.
Blocks transmission of itch signals to the spinal cord and brain.
Provides targeted itch relief without broad immune suppression.
Starts controlling itch within 24 hours.
Provides long-lasting relief for at least 6 weeks (6–8 weeks duration).
Helps improve comfort and quality of life in dogs suffering from chronic allergic itch.
Class:
Canine Anti-IL-31 Monoclonal Antibody / Biological Dermatology Therapy
Indication / Uses:
Treatment of dogs against allergic dermatitis.
Treatment of canine atopic dermatitis (CAD).
Management of allergic pruritus (itching).
Long-term control of IL-31 mediated itch.
Suitable for tailored dermatology management plans.
Dosage and administration:
Route: Subcutaneous (SC) injection only.
Administer as an in-clinic injection.
Dose every 6–8 weeks or as needed based on individual patient response.
Demonstrated safe when administered every 4 weeks in studies.
Minimum dosing guidance:
Minimum dose: 0.05 mL/lb (0.11 mL/kg) body weight.
Dosing chart:
Dog Weight | Total Dose Volume |
| 5–10 lb (2.3–4.5 kg) | 0.5 mL |
| 10.1–20 lb (4.6–9.1 kg) | 1.0 mL |
| 20.1–30 lb (9.2–13.6 kg) | 1.5 mL |
| 30.1–40 lb (13.7–18.1 kg) | 2.0 mL |
| 40.1–50 lb (18.2–22.7 kg) | 2.5 mL |
| 50.1–60 lb (22.8–27.2 kg) | 3.0 mL |
| 60.1–70 lb (27.3–31.7 kg) | 3.5 mL |
| 70.1–80 lb (31.8–36.3 kg) | 4.0 mL |
| 80.1–90 lb (36.4–40.8 kg) | 4.5 mL |
| 90.1–100 lb (40.9–45.4 kg) | 5.0 mL |
| 100.1–110 lb (45.5–49.9 kg) | 5.5 mL |
| 110.1–120 lb (50–54.4 kg) | 6.0 mL |
Administration instructions:
Withdraw appropriate volume from vial(s).
Administer full dose subcutaneously.
Repeat administration every 6–8 weeks when required.
Overdoses / Side effects / Contraindications / Warnings:
Side Effects:
Injection site reactions may occur.
Reported reactions were generally mild and self-limiting.
Injection reactions typically resolved within one day.
Field safety profile was comparable with placebo.
Warnings / Precautions:
Veterinary use only.
Monitor dermatology patients regularly.
Before repeat injections evaluate:
New skin lesions or lumps
Ear discharge or odour
Change in itch level
Appetite or energy changes
Any unexpected clinical signs
Contraindications:
No specific contraindications mentioned in supplied literature.
Pharmaceutical precautions / Instructions:
Single-use vials only.
Discard vial after puncture.
Do not split vials between patients.
Store upright in original packaging.
Refrigerate at 2°C–8°C (35–46°F).
Do not freeze.
Safety: Age / Pregnancy / Withdrawal:
No age restriction reported.
No weight restriction reported.
Demonstrated safe in laboratory and field studies.
Companion animal product – withdrawal period not applicable.
Substitute: Cytopoint (Lokivetmab injection),
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.